232 related articles for article (PubMed ID: 1329219)
1. Second-line carboplatin-based chemotherapy for small cell lung cancer: the Groningen experience.
Postmus PE; Smit EF; Berendsen HH; Haaxma-Reiche H
Semin Oncol; 1992 Feb; 19(1 Suppl 2):17-23. PubMed ID: 1329219
[TBL] [Abstract][Full Text] [Related]
2. Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: an EORTC Phase III trial.
Postmus PE; Scagliotti G; Groen HJ; Gozzelino F; Burghouts JT; Curran D; Sahmoud T; Kirkpatrick A; Giaccone G; Splinter TA
Eur J Cancer; 1996 Aug; 32A(9):1498-503. PubMed ID: 8911108
[TBL] [Abstract][Full Text] [Related]
3. Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.
Hawkins DS; Felgenhauer J; Park J; Kreissman S; Thomson B; Douglas J; Rowley SD; Gooley T; Sanders JE; Pendergrass TW
Cancer; 2002 Sep; 95(6):1354-65. PubMed ID: 12216105
[TBL] [Abstract][Full Text] [Related]
4. Testing the possible non-cross resistance of two equipotent combination chemotherapy regimens against small-cell lung cancer: a phase II study of the EORTC Lung Cancer Cooperative Group.
Postmus PE; Smit EF; Kirkpatrick A; Splinter TA
Eur J Cancer; 1993; 29A(2):204-7. PubMed ID: 8380697
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of the combination of carboplatin and ifosfamide in previously untreated metastatic small cell lung carcinoma.
Le Chevalier T; Thomas F; Subirana R; Baldeyrou P; Ruffie P; Arriagada R; Chazard M; Tursz T
Cancer; 1991 Jun; 67(12):2980-3. PubMed ID: 1646067
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study.
Wolff AC; Ettinger DS; Neuberg D; Comis RL; Ruckdeschel JC; Bonomi PD; Johnson DH
J Clin Oncol; 1995 Jul; 13(7):1615-22. PubMed ID: 7602350
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer.
Strauss GM; Lynch TJ; Elias AD; Jacobs C; Kwiatkowski DJ; Shulman LN; Carey RW; Grossbard ML; Jauss S; Sugarbaker DJ
Semin Oncol; 1995 Aug; 22(4 Suppl 9):70-4. PubMed ID: 7544029
[TBL] [Abstract][Full Text] [Related]
8. The place of ifosfamide in chemotherapy of small cell lung cancer: the Eastern Cooperative Oncology Group experience and a selected literature update.
Ettinger DS
Semin Oncol; 1995 Feb; 22(1 Suppl 2):23-7. PubMed ID: 7846538
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of ifosfamide in combination with carboplatin and etoposide in small cell lung cancer.
Lee HS; Lee YG; Koo DH; Oh S; Nam H; Song JU; Lim SY; Lim SY; Lee SS
Cancer Chemother Pharmacol; 2015 Nov; 76(5):933-7. PubMed ID: 26374553
[TBL] [Abstract][Full Text] [Related]
10. Phase II and III studies with carboplatin in small cell lung cancer.
Gatzemeier U; Hossfeld DK; Neuhauss R; Reck M; Achterrath W; Lenaz L
Semin Oncol; 1992 Feb; 19(1 Suppl 2):28-36. PubMed ID: 1329220
[TBL] [Abstract][Full Text] [Related]
11. Carboplatin, etoposide, and ifosfamide as intensive chemotherapy for small-cell lung cancer.
Smith IE; Perren TJ; Ashley SA; Woodiwiss J; Forgeson GV; Yarnold JR; Ford HT
J Clin Oncol; 1990 May; 8(5):899-905. PubMed ID: 2159056
[TBL] [Abstract][Full Text] [Related]
12. Etoposide/vincristine-based chemotherapy with or without carboplatin in extensive-stage small cell lung cancer: a prospective randomized phase III trial.
Gatzemeier U; Pawel JV; Laumen R; Hossfeld DK; Neuhauss R
Semin Oncol; 1994 Jun; 21(3 Suppl 6):31-5. PubMed ID: 8052871
[TBL] [Abstract][Full Text] [Related]
13. Experience of a German multicenter study group with ifosfamide in small cell lung cancer.
Havemann K; Wolf M; Drings P; Hans K; Schroeder M; Holle R; Flechtner H; Goerg R; Becker H
Semin Oncol; 1989 Feb; 16(1 Suppl 3):9-18. PubMed ID: 2539648
[TBL] [Abstract][Full Text] [Related]
14. Dose intensity phase I/II trial with carboplatin, ifosfamide, etoposide and vincristine combined with filgrastim in patients with small-cell lung cancer.
Hanauske AR; Korfel A; Perker M; Heinrich B; Schwab G; Graf M; Depenbrock H; Höffken G; Kreuser ED; Thiel E; Zwingers T; Berdel WE
Oncology; 1997; 54(5):363-70. PubMed ID: 9260596
[TBL] [Abstract][Full Text] [Related]
15. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine.
Johnson BE; Bridges JD; Sobczeck M; Gray J; Linnoila RI; Gazdar AF; Hankins L; Steinberg SM; Edison M; Frame JN; Pass H; Nesbitt J; Holden D; Mulshine JL; Glatstein E; Ihde DC
J Clin Oncol; 1996 Mar; 14(3):806-13. PubMed ID: 8622028
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck.
Shin DM; Glisson BS; Khuri FR; Lippman SM; Ginsberg L; Diaz E; Papadimitrakopoulou V; Feng L; Francisco M; Garden A; Kies MS; Myers J; Clayman G; Hong WK
Cancer; 2002 Jul; 95(2):322-30. PubMed ID: 12124833
[TBL] [Abstract][Full Text] [Related]
17. Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK).
Joss RA; Alberto P; Hürny C; Bacchi M; Leyvraz S; Thürlimann B; Cerny T; Martinelli G; Stahel R; Ludwig C
Ann Oncol; 1995 Jan; 6(1):41-8. PubMed ID: 7536028
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
Wolf M; Havemann K; Holle R; Gropp C; Drings P; Hans K; Schroeder M; Heim M; Dommes M; Mende S
J Clin Oncol; 1987 Dec; 5(12):1880-9. PubMed ID: 2824710
[TBL] [Abstract][Full Text] [Related]
19. The multidrug resistant phenotype in clinical practice; evaluation of cross resistance to ifosfamide and mesna after VP16-213, doxorubicin and vincristine (VPAV) for small cell lung cancer.
Cantwell BM; Bozzino JM; Corris P; Harris AL
Eur J Cancer Clin Oncol; 1988 Feb; 24(2):123-9. PubMed ID: 2833398
[TBL] [Abstract][Full Text] [Related]
20. Ifosfamide, carboplatin, and etoposide with midcycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: clinical and quality-of-life results of the British Medical Research Council multicenter randomized LU21 trial.
Thatcher N; Qian W; Clark PI; Hopwood P; Sambrook RJ; Owens R; Stephens RJ; Girling DJ
J Clin Oncol; 2005 Nov; 23(33):8371-9. PubMed ID: 16293867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
